评价的乳酸菌cillus casei 39 Paraprobiotic 在调节炎症和氧化途径在酸诱导性结肠炎
1Food Processing Department, Food Quality Control and Analysis Programme, Çine Vocational School Aydin Adnan Menderes University Aydin Türkiye.
Food science & nutrition
|July 21, 2025
概括
紫外线C失活的乳酸酶菌cillus casei 39 (偏微生物) 在老鼠中有效治疗性结肠炎 (UC). 这种神经生物体显示出显著的抗炎,抗氧化和抗丧作用,为UC提供了有前途的治疗方法.
科学领域:
- 胃肠病学 胃肠病学
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病,其特征是粘膜炎症,氧化应激和亡.
- 目前对UC的治疗有局限性,需要探索新的治疗策略.
研究的目的:
- 为了研究UV-C无活化的*Lacticaseibacillus casei*39 (偏微生物) 在酸诱导的性结肠炎的老鼠模型中的治疗潜力.
- 评估对临床症状,炎症标志物,氧化应激,生长因子,PI3K/AKT通路和亡的影响.
主要方法:
- 建立了一种由乙酸诱导的性结肠炎 (UC) 鼠标模型.
- 鼠被用*L. casei* 39益生菌或其UV-C无活化的类型治疗.
- 评估了临床症状,炎症性细胞因子 (TNF-α,IL-6,IL-10),氧化应激标志物 (TOC,TAC),生长因子表达 (VEGF,EGF),PI3K/AKT通路激活,以及亡标志物 (Bax/Bcl-2,Caspase-3).
主要成果:
- 副生物治疗显著改善了UC的临床症状,减少了促炎性细胞因子 (TNF-α,IL-6) 和增加了抗炎性细胞因子 (IL-10).
- 通过降低总氧化能力 (TOC) 和增加总抗氧化能力 (TAC),治疗有效地减少了氧化应激.
- 偏益生菌剂的使用抑制了PI3K/AKT信号传递,并降低了包括Bax/Bcl-2比率和Caspase-3表达在内的亡标志物.
结论:
- 在性结肠炎的背景下,UV-C失活的 *Lacticaseibacillus casei* 39 类偏生菌表现出强大的抗炎,抗氧化和抗质性质.
- 这种类型的副生物体代表了一种有前途的,多目标的治疗药物,用于治疗性结肠炎.
更多相关视频
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
12.4K
06:24Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
Published on: October 13, 2023
1.1K
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
239
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
239
01:21Drugs for Treatment of Constipation-Predominant IBS
342
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
342
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
424
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
424
01:29Inflammatory Bowel Disease IV: Pharmacological Management
196
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
196
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
329
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
329
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
528
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
528